– FRANCE, Velizy-Villacoublay – CARMAT (EPA: ALCAR), designer and developer of the world’s most advanced total artificial heart, today announced the appointment of Alexandre Conroy to its Board of Directors replacing Jean-Pierre Garnier who is standing down as Chairman of the Board.
“I am very pleased to now be able to team up with Mr. Alexandre Conroy. We will be able to rely on his exceptional experience in the health industry to ensure the development of our innovative therapy”, said CEO, Stéphane Piat.
About Alexandre Conroy
A graduate of HEC business school in Paris, Alexandre Conroy started in the pharmaceutical and biotechnology industries. He then spent most of his career at Becton Dickinson & Co (NYSE), a group specializing in medical devices, diagnostics,s and life sciences. During his 31 years with that company, he was notably President of the Pharmaceutical Systems unit, President for the Americas and EMEA regions,x and President of the Medication Delivery Solutions unit, in growth, turnaround, and acquisition integration contexts. From 2019 to 2022, Alexandre Conroy led the group’s global industrial operations within the context of the COVID-19 pandemic and its impacts on supply chains.
Alexandre Conroy has been a member of the Executive Committee and a Corporate Officer at Becton Dickinson & Co. His career has also led him to live in Argentina, the United States, and Europe.
Alexandre Conroy said: “I have spent my entire career in the medical technologies industry, and the Aeson heart represents what can be described as a genuine groundbreaking innovation. This device has immense potential and can become a new standard in the management of heart failure. I am very pleased to be able to contribute to its development with the rest of the Board of Directors and the managerial team. I have no doubt that, surrounded by such talented teams, we will be able to make the most of Aeson’s medical potential for the benefit of patients, and make CARMAT a success story in the French medical industry”.
About CARMAT
CARMAT is a French MedTech that designs, manufactures, and markets the Aeson artificial heart. The Company’s ambition is to make Aeson the first alternative to a heart transplant and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world’s first physiological artificial heart that is highly hemocompatible, pulsatile, and self-regulated, Aeson could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system continuously connected to the implanted prosthesis. Aeson is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson is also currently being assessed within the framework of an Early Feasibility Study in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices in Vélizy-Villacoublay and its production site in Bois-d’Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of more than 200 highly specialized people.
For more information: https://www.carmatsa.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.